Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology

NCT ID: NCT01887509

Last Updated: 2018-05-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-07

Study Completion Date

2017-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This innovative study will involve the use of probe-based confocal laser endomicroscopy, a new medical imaging technology never used for surgical indications to date. Virtual biopsies (pCLE images) will be compared to histopathology analysis.

This study focuses on the evaluation of rectal tumor margins. The hypothesis is that pCLE will allow identification of rectal tumor margin, comparable to that of histopathology. In the future, decision of resection margin could rely on intraoperative pCLE exam.

The proposed study is a feasibility study, first in the indication of rectal cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Defining the limits of resection of rectal tumors is often imprecise. The identification of the banks of a tumor becomes critical when it comes to the decision to potentially sacrifice the sphincter during the surgical resection. Currently tumor margins are identified by direct examination by the surgeon, or using flexible endoscopy. Endoscopy and confocal microscopy could provide precise images of tumor enabling the reliable definition of resection margins.

There would be a direct benefit for the patient, whom sphincter could be preserved. pCLE (probe-based Confocal Laser Endomicroscopy) has already been widely used for colorectal lesions, and its value proposition has been demonstrated and validated in several studies. This study is the first using pCLE intraoperatively. Study results may lead the use of pCLE to validate surgical procedure decision (resection margin) and to a revision of patient management for colorectal cancer, by adapting neoadjuvant radiochemotherapy to the patient's responder status.

The goal is to identify tumor margin (lower pole) to optimize the resection margin, and to limit resection of healthy rectal tissue for optimal anal sphincter preservation. Moreover, determining the optimal date of surgery following neoadjuvant radiochemotherapy in rectal cancer is being discussed and no consensus has been reached. Therefore, to date, there is no formal evaluation of tumor response. This is partly due to the lack of information on tumor state and tumor evolution over time, between the end of radiochemotherapy and surgery. Histological follow up of tumor would provide supporting information to fill this gap. However, frequent tumor biopsies are not possible. Alternatively, probe-based confocal laser endomicroscopy (pCLE) could allow for a sequential analysis of tumor response. Response to treatment could be assessed and used to define optimal date of surgical resection, depending on patient responding status to treatment. Responding patients would undergo surgery at a later date than non-responders, in whom surgery could be performed earlier.

Benefits of the study lay in the more accurate definition of resection margins, with its associated potential therapeutic impact of the anal sphincter preservation and in the definition of the optimal date of rectal tumor resection, based on response status to radiochemotherapy.

Study interests are :

* Microscopic structure of tumor will be analyzed at the cellular and microvascular levels and compared to healthy mucosa.
* Evolution of response during and following radiochemotherapy will be assessed, and will help classify patients as responders/non responders.
* pCLE results will be compared to histopathology results on pre-treatment and resection biopsies.
* Images gathered through the imaging modalities (WLE, pCLE, EUS) along with histopathology results will be combined to create an atlas and database of rectal tumors.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rectal Cancer Rectal Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probe-based confocal laser endomicroscopy

Patients will undergo:

* Conventional rectoscopy
* pCLE exam following injection of fluorescein, fluorescent contrast agent
* EUS : echoendoscopy
* Biopsies for histopathology : location identical to those of pCLE
* Tumor resection will be performed according to standard oncologic principles.

All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.

Biopsies will be harvested in both healthy and tumor tissue as well.

After all procedures are complete, a second assessment of pCLE images by a third party will be performed.

Intervention Type DEVICE

Rectoscopy

Patients will undergo:

* Conventional rectoscopy
* pCLE exam following injection of fluorescein, fluorescent contrast agent
* EUS : echoendoscopy
* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.

All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.

Both healthy and tumor tissue will be examined.

Intervention Type PROCEDURE

EUS

Patients will undergo:

* Conventional rectoscopy
* pCLE exam following injection of fluorescein, fluorescent contrast agent
* EUS : echoendoscopy
* Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.

All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.

Intervention Type PROCEDURE

Biopsy and resection

Patients will undergo:

* Conventional rectoscopy
* pCLE exam following injection of fluorescein, fluorescent contrast agent
* EUS : echoendoscopy
* Biopsies for histopathology : location identical to those of pCLE
* Tumor resection will be performed according to standard oncologic principles.

All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.

Biopsies will be harvested in both healthy and tumor tissue as well.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cellvizio® with ColoFlex probe Echoendoscopy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient, male or female over 18 years old
* Patient with rectal adenocarcinoma :

* stage T1 or T2, N0 (one single evaluation, during resection)
* stage N+ or T3 (pre- and post-radiochemotherapy evaluations)
* Absence of contra-indication to rectoscopy conduct
* Patient able to understand the study and to provide written informed consent
* Patient registered with the French social security regime


* Absence of written informed consent
* Patient with known or suspected allergy to fluorescein
* Patient with history of reaction jeopardizing the vital prognosis during angiography
* Patient with history of multiple or serious allergic reaction to drugs
* Patient presenting, in the investigator's judgment, a condition or disease preventing their participation to study procedures
* Patient pregnant or breast-feeding
* Patient within exclusion period from other clinical trial
* Patient having forfeited their freedom of an administrative or legal obligation
* Patient being under guardianship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IHU Strasbourg

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joël Leroy, Pr

Role: PRINCIPAL_INVESTIGATOR

Service de Chirurgie Disgestive et Endocrinienne - Nouvel Hôpital Civil - Strasbourg

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de chirurgie digestive et endocrinienne - Nouvel Hôpital Civil

Strasbourg, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Wijsmuller AR, Ghnassia JP, Varatharajah S, Schaeffer M, Leroy J, Marescaux J, Ignat M, Mutter D. Prospective Trial on Probe-Based Confocal Laser Endomicroscopy for the Identification of the Distal Limit in Rectal Adenocarcinoma. Surg Innov. 2018 Aug;25(4):313-322. doi: 10.1177/1553350618773011. Epub 2018 May 7.

Reference Type RESULT
PMID: 29732957 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-A00406-39

Identifier Type: OTHER

Identifier Source: secondary_id

12-005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.